Recurrence Risk in Pediatric Noninfectious Uveitis During Adalimumab Tapering: An International Multicenter Retrospective Study
Main finding · NIU recurrence at adalimumab taperingResult — go to the resultHazard ratio 0.40 95% CI 0.21–0.74Authors' conclusion
This study highlights the significant clinical impact of ADA tapering on uveitis recurrence risk
Study context
- Population
- Pediatric patients with noninfectious uveitis (NIU) who underwent adalimumab tapering due to inactive uveitis65 girls
- Participants
- 114 patients
- Exposure
- Slower vs faster adalimumab tapering schedule
- Outcome
- NIU recurrence during adalimumab tapering
Methodological detailsmulticentre, international, Cox proportional hazards regression
- Multicentre
- International
- Cox proportional hazards regression
Main finding
NIU recurrence at adalimumab tapering
Hazard ratio
0.40
95% CI 0.21–0.74
P < 0.01
Slower taperingvs Faster tapering
HR 0.40 (95% CI 0.21–0.74); P < 0.01
As reported in the abstract
- Patients with NIU recurrence
- 53 of 114; 46%
- Median time to recurrence from start of tapering (IQR 15-58 weeks)
- 30 weeks
Observational data: associations, not effects.
Further findings
Recurrence by ≥2 years of disease inactivity before tapering (JIA-U subgroup)
| HR (95% CI) | P value | ||
|---|---|---|---|
| Tapering after ≥2 years inactivity | 0.65 (0.43–0.95) | P = 0.05 | |
| 0.512Hazard ratio (log scale) |
Recurrence rate among patients who discontinued ADA (59; 52%)
P = 0.6
Median time to recurrence among patients who discontinued ADA
P = 0.05
Original publication
Recurrence Risk in Pediatric Noninfectious Uveitis During Adalimumab Tapering: An International Multicenter Retrospective Study. Arthritis Rheumatol. Published 13 May 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →